The Pangenomic Vision: Personalized Digital Health for the Mind
Positioned at the intersection of personalized healthcare and digital innovation, the company is building a platform that empowers individuals to take control of their mental health through data-driven insights, AI-powered tools, and science-backed natural remedies.
With mental health concerns on the rise globally, demand for scalable, non-invasive solutions is stronger than ever. Pangenomic Health’s business model uniquely combines technology, accessibility, and alternative care to serve a growing population seeking relief beyond pharmaceuticals. The company’s approach not only provides therapeutic tools but also fosters long-term behavioral change—establishing a recurring, high-retention user base across its product ecosystem.
Pangenomic Health is developing a new standard for how people understand and manage mental wellness. By combining traditional healing knowledge with AI-powered digital tools, the company is creating a comprehensive support system for consumers who are seeking alternatives to conventional medications.
The company’s wellness platform is structured to deliver hyper-personalized experiences based on continuous user feedback, health tracking, and emotional data mapping. Over time, these interactions refine the platform’s effectiveness, creating a dynamic health journey that evolves alongside each user. This adaptive model allows Pangenomic to remain relevant and supportive throughout an individual’s life—an essential factor in building trust and value in the wellness space.
5 Reasons Why Pangenomic Health Inc. is Positioned for Growth
✅ Rising Global Demand for Mental Health Support | The mental wellness industry is expected to reach $130 billion by 2027. With rising anxiety, burnout, and depression levels, demand for scalable, affordable solutions like Pangenomic’s platform is surging. This wave of demand creates a rare opportunity for early investors to gain exposure to an industry at the start of a sustained growth curve.
✅ Proprietary Digital Therapeutics Platform | Pangenomic’s platform integrates AI, user behavior data, and natural health protocols to deliver personalized wellness recommendations. This positions the company as a leader in a rapidly growing digital therapeutics space. Unlike generic wellness apps, Pangenomic focuses on evidence-based, integrative solutions with measurable outcomes—bridging the gap between consumer wellness and clinical care.
✅ Focus on Plant-Based, Non-Pharmaceutical Interventions | With consumers increasingly shifting toward natural health solutions, Pangenomic’s emphasis on plant-based remedies and evidence-backed protocols aligns with macro-level consumer health trends. This commitment also differentiates the company from pharmaceutical players, offering an appealing option for users seeking a more holistic approach to mental health.
✅ Strategic Product Ecosystem | The company operates a growing suite of mental wellness apps, which together create a recurring revenue model and provide scalable access to global users seeking mental health tools and education. These apps are cross-integrated, allowing users to transition seamlessly between tracking, education, and treatment—all within a unified ecosystem.
✅ Strengthened Capital Position and Restructuring | Recent financings and management changes signal a refreshed operational focus. Despite filing delays, Pangenomic is actively working to stabilize its foundation and accelerate forward-looking initiatives. The company’s transparency during this restructuring phase suggests a commitment to accountability and long-term shareholder trust.
A Technology-Driven Approach to Mental Wellness
Pangenomic Health’s digital platform is built to serve individuals with mild to moderate mental health challenges—conditions that often go untreated due to stigma or lack of access. By offering clinically informed, AI-guided tools, the company lowers the barriers to care while ensuring solutions are tailored to each user.
The platform supports journaling, daily mental health check-ins, progress tracking, and suggested behavioral interventions in real time. It is designed to help users identify emotional patterns and triggers through intuitive interfaces and non-judgmental guidance. As the technology becomes more refined through machine learning, the system becomes even more precise in delivering actionable wellness strategies—strengthening its competitive edge over static mental health apps.
Restructuring and Financial Realignment
While Pangenomic Health has faced regulatory challenges related to financial filings, the company has been transparent in its steps to correct course. Over the past several months, the team has implemented key leadership changes, repriced outstanding warrants, and completed private placements to strengthen its working capital.
In addition to administrative changes, the company has also made strides to optimize operational expenses and focus on revenue-generating activities across its digital product suite. This leaner, more agile structure will allow Pangenomic to scale with less friction while appealing to investors looking for capital-efficient business models in healthcare. The foundation is being laid for a disciplined, growth-focused rebound.
Aligning with Macro Trends in Wellness and Data-Driven Care
The convergence of health data, personalization, and preventive wellness is reshaping how the world approaches mental health. Pangenomic Health is positioned at the forefront of this shift, providing solutions that meet rising consumer expectations for natural, tech-enabled support.
In a landscape where traditional healthcare often fails to meet modern mental wellness needs, Pangenomic offers a compelling hybrid of convenience, data science, and holistic care. Its expanding product suite, combined with potential B2B licensing opportunities, positions the company not just as a consumer brand—but as a valuable partner to healthcare providers, insurers, and corporate wellness programs.
Meet the Team
Maryam Marissen | CEO
Maryam has served in almost every facet of business — as a founder, board member, consultant, and now the CEO of PanGenomic. Her pursuit of excellence has pushed her to master a wide array of skill sets spanning consumer product marketing, private clinical services, public relations, and social advocacy, but the democratization of healthcare remains her primary mission.
Robert Whitelaw | Chief Investment Strategist
Robert co-founded the biotech company Havn Life Sciences (CSE: HAVN) and served as a founding director of Psy Integrated Health Corp. He was also involved in establishing the Vancouver-based Empower Health clinic. In addition to these ventures, Robert co-founded the ETC3 Tech Centre located in the Research Campus of UBC. Prior to his involvement in these ventures, Robert served as the CEO of Epic Data and Fincentric.
Vincent Lum | Co-Founder, CEO, Director
Vincent has over 20 years of experience in the life sciences industry, where he has held several C-level positions. He is currently the CEO of MUJN Diagnostics. Vincent also co-founded Cardio-digital, which was later acquired by Medtronic. Prior to that, he served as Vice President and Partner at MDS Capital and Royal Bank Venture Capital.
Important Information
Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Fund, please call (844)875-2288 or visit www.vistashares.com. Read the prospectus or summary prospectus carefully before investing.
Investing involves risk, including possible loss of principal. The BITA VistaShares Artificial Intelligence Supercycle Index is a rules-based composite index that tracks the market performance of companies, listed on global stock exchanges, that derive their revenues from producing high performance semiconductors, and building and operating AI-enabled applications and datacenters.
Artificial Intelligence Risk. Common stocks are generally exposed to greater risk than other types of securities, such as preferred stock and debt obligations, because common stockholders generally have inferior rights to receive payment from specific issuers. Technology Sector Risks. The Fund will invest substantially in companies in the technology sector, and therefore the performance of the Fund could be negatively impacted by events affecting this sector.
Concentration Risk. To the extent that the Fund concentrates in an industry, it will be subject to the risk that economic, political, or other conditions that have a negative effect on that industry will negatively impact the Fund to a greater extent than if its assets were invested in a wider variety of industries.
New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have an extensive track record or history on which to base their investment decisions.
Foreside Fund Services, LLC, distributor. Foreside Fund Services is not affiliated with VistaShares or Stock Research Today.
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to agreement with Vista Shares, TIA expects to be paid a total of $60k for a period beginning on 1.29.25 thru 7.29.25.. Pursuant to an agreement between TIA and Wolf financial LLC, Wolf expects to be paid 48k total for a period beginning on 1.29.25 thru 7.29.25.
